Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fezolinetant PK in Prostate Cancer Patients on Hormone Therapy
NCT07783282Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of fezolinetant in hot flashes (4 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Concentration and Area under the concentration-time curve from the time of dosing extrapolated to time infinity. Started Sep 2026; status: recruiting.
02
Drugs
fezolinetant
03
Conditions
hot flashes
Beyond the preview
Go deeper on NCT07783282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783282.